Pharmaxis Completes Phase II clinical study with ASM8 in asthma patients
11th
Mar 10
Release Date: 11/03/2010 12:00am
Pharmaxis Ltd today announced the successful completion of a Phase IIa dose profiling study with its new anti-inflammatory agent ASM8 in patients with allergic asthma.
Categories: News and Media